NKTR

In the past six months (March 2026 to September 2026), Nektar Therapeutics' stock was impacted by several events. In February 2026, the company completed a public offering of common stock, raising $460 million, followed by another offering in April 2026, generating $373.8 million. May 2026 saw positive first-quarter financial results with increased cash and investments, and positive maintenance data from its REZOLVE-AD Phase 2b study. In July 2026, the Phase 3 ZENITH-AD program for atopic dermatitis was initiated. However, August 2026 second-quarter financial results indicated a decline in revenue and ongoing cash burn, despite a narrowed net loss, and insider selling by executives continued. In August 2026, Nektar announced the publication of positive Phase 2b REZOLVE-AD 16-Week Induction Results in The Lancet. More recently, in September 2026, the stock experienced a significant drop due to a jury deliberation in a dispute with Eli Lilly over its Rezpeg drug and a hedge fund (Squarepoint Ops LLC) slashing its position by over 94%. The stock has shown volatility, with a 34% decrease over the past three months, but a 14.2% gain over the last 12 months as of September 18, 2026, and a year-to-date return of 62.41% as of September 11, 2026.